A phase 4, monocenter, randomized, open label, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 8-week treatment with the glucagon-like peptide-1 receptor agonist lixisenatide versus insulin glulisine on renal physiology and biomarkers in insulin glargine-treated patients with type 2 diabetes mellitus

Trial Profile

A phase 4, monocenter, randomized, open label, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 8-week treatment with the glucagon-like peptide-1 receptor agonist lixisenatide versus insulin glulisine on renal physiology and biomarkers in insulin glargine-treated patients with type 2 diabetes mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 May 2016

At a glance

  • Drugs Lixisenatide (Primary) ; Insulin glulisine
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms ELIXIRS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Apr 2016 Status changed from recruiting to completed.
    • 08 Feb 2016 Planned End Date changed from 1 Feb 2016 to 1 Jul 2016 as per ClinicalTrials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top